

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 13, 2025 (the “**Prospectus**”) issued by TransThera Sciences (Nanjing), Inc. (藥捷安康(南京) 科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of our Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about our Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. Our Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, CLSA Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail in an open market for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be conducted at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering, being July 18, 2025.

Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong). Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which will begin on the Listing Date and is expected to expire on July 18, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the H Shares, and therefore the price of the H Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall, in their sole and absolute discretion, be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on June 23, 2025).

In connection with the Global Offering, our Company expects to grant the Over-allotment Option to the International Underwriters, exercisable by the Overall Coordinators at their sole and absolute discretion on behalf of the International Underwriters at any time from the Listing Date until July 18, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Pursuant to the Over-allotment Option, the Overall Coordinators will have the right to require our Company to allot and issue, at the Offer Price, up to an aggregate of additional 2,292,000 H Shares, representing in aggregate approximately 15.0% of the number of the Offer Shares initially available under the Global Offering to cover over-allotment in the International Offering, if any.

TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Global Offering

| | |
|---|--|
| Number of Offer Shares under the Global Offering | : 15,281,000 H Shares (subject to the Over – allotment Option) |
| Number of Hong Kong Offer Shares | : 1,528,500 H Shares (subject to reallocation) |
| Number of International Offer Shares | : 13,752,500 H Shares (subject to reallocation and the Over-allotment Option) |
| Offer Price | : HK\$13.15 per H Share, plus brokerage 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars and subject to refund) |
| Nominal value | : RMB1.00 per H Share |
| Stock code | : 2617 |

***Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers***

(In no particular order)



CITIC SECURITIES



华泰国际
HUATAI INTERNATIONAL

***Overall Coordinator, Joint Global Coordinator,
Joint Bookrunner and Joint Lead Manager***



交銀國際
BOCOM International

Joint Bookrunners and Joint Lead Managers



中銀國際 BOCI



招銀国际
CMB INTERNATIONAL



浦銀國際
SPB INTERNATIONAL



TradeGo Markets

**IMPORTANT NOTICE TO INVESTORS:
FULLY ELECTRONIC APPLICATION PROCESS**

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus to the public in relation to the Hong Kong Public Offering.

The Prospectus is available at the website of the Hong Kong Stock Exchange at www.hkexnews.hk under the “HKEXnews > New Listings > New Listing Information” section, and our website at www.transthera.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

To apply for the Hong Kong Offer Shares, you may use one of the following application channels:

| Application Channel | Platform | Target Investors | Application Time |
|---|--|---|---|
| HK eIPO White Form service | www.hkeipo.hk | Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name. | From 9:00 a.m. on Friday, June 13, 2025 to 11:30 a.m. on Wednesday, June 18, 2025, Hong Kong time. The latest time for completing full payment of application monies will be 12:00 noon on Wednesday, June 18, 2025, Hong Kong time. |
| HKSCC EIPO channel | Your broker or custodian who is a HKSCC Participant will submit a HKSCC EIPO application on your behalf through HKSCC’s FINI system in accordance with your instruction. | Investors who would not like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant’s stock account. | Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian. |

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed document as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong).

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table below. You are required to pay the amount next to the number you select.

Your application through the HK eIPO White Form service or the HKSCC EIPO channel must be made for a minimum of 500 Hong Kong Offer Shares and in multiples of that number of Hong Kong Offer Shares as set out in the table below. No application for any other number of Hong Kong Offer Shares will be considered and such an application is liable to be rejected. If you are applying through the HK eIPO White Form service, you may refer to the table below for the amount payable for the number of Shares you have selected. You must pay the respective amount payable on application in full upon application for Hong Kong Offer Shares. If you are applying through the HKSCC EIPO channel, you are required to pre-fund your application based on the amount specified by your broker or custodian, as determined based on the applicable laws and regulations in Hong Kong.

| No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment <i>HK\$</i> | No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment <i>HK\$</i> | No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment <i>HK\$</i> | No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment <i>HK\$</i> |
|--|---|--|---|--|---|--|---|
| 500 | 6,641.31 | 7,000 | 92,978.33 | 50,000 | 664,130.89 | 400,000 | 5,313,047.10 |
| 1,000 | 13,282.62 | 8,000 | 106,260.94 | 60,000 | 796,957.06 | 450,000 | 5,977,177.99 |
| 1,500 | 19,923.92 | 9,000 | 119,543.57 | 70,000 | 929,783.24 | 500,000 | 6,641,308.88 |
| 2,000 | 26,565.24 | 10,000 | 132,826.18 | 80,000 | 1,062,609.42 | 600,000 | 7,969,570.66 |
| 2,500 | 33,206.55 | 15,000 | 199,239.27 | 90,000 | 1,195,435.60 | 700,000 | 9,297,832.43 |
| 3,000 | 39,847.86 | 20,000 | 265,652.35 | 100,000 | 1,328,261.78 | 764,000 ⁽¹⁾ | 10,147,919.96 |
| 3,500 | 46,489.16 | 25,000 | 332,065.44 | 150,000 | 1,992,392.67 | | |
| 4,000 | 53,130.47 | 30,000 | 398,478.53 | 200,000 | 2,656,523.56 | | |
| 4,500 | 59,771.78 | 35,000 | 464,891.62 | 250,000 | 3,320,654.43 | | |
| 5,000 | 66,413.09 | 40,000 | 531,304.71 | 300,000 | 3,984,785.33 | | |
| 6,000 | 79,695.71 | 45,000 | 597,717.80 | 350,000 | 4,648,916.21 | | |

- (1) Maximum number of Hong Kong Offer Shares you may apply for and this is approximately 50% of the Hong Kong Offer Shares initially offered.
- (2) The amount payable is inclusive of brokerage, SFC transaction levy, the Hong Kong Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) or to the **HK eIPO White Form Service Provider** (for applications made through the application channel of the **HK eIPO White Form service**) while the SFC transaction levy, the Hong Kong Stock Exchange trading fee and the AFRC transaction levy will be paid to the SFC, the Hong Kong Stock Exchange and the AFRC, respectively.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

APPLICATION FOR LISTING ON THE HONG KONG STOCK EXCHANGE

We have applied to the Listing Committee of the Hong Kong Stock Exchange for the listing of, and permission to deal in, our H Shares to be issued pursuant to the Global Offering and any H Shares to be converted from Unlisted Shares.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 1,528,500 H Shares (subject to reallocation) in Hong Kong, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 13,752,500 H Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and the Guide of New Listing Applicants issued by the Hong Kong Stock Exchange (the “**Guide**”), the Overall Coordinators may, at their sole discretion, reallocate Offer Shares initially allocated for the International Offering to the Hong Kong Public Offering. In accordance with Practice Note 18 of the Listing Rules and Chapter 4.14 of the Guide, if such reallocation is done other than pursuant to the clawback mechanism as described in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus, the maximum total number of Offer Shares that may be allocated to the Hong Kong Public Offering following such reallocation shall be not more than 3,057,000 Offer Shares, representing two times of the initial allocation to the Hong Kong Public Offering.

Under the International Underwriting Agreement, we expect to grant to the International Underwriters, exercisable by the Overall Coordinators (for themselves and on behalf of the International Underwriters), the Over-allotment Option, which will be exercisable from the Listing Date until up to (and including) the 30th day after the last day for lodging applications under the Hong Kong Public Offering (the last day for exercise of the Over-allotment Option being July 18, 2025), to require us to issue up to an aggregate of 2,292,000 H Shares, representing no more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover over-allocations in the International Offering, if any. In the event that the Over-allotment Option is exercised, an announcement will be made on the website of the Hong Kong Stock Exchange (www.hkexnews.hk) and on our website (www.transthera.com), respectively.

PRICING

The Offer Price will be HK\$13.15 per Offer Share unless otherwise announced. Applicants under the Hong Kong Public Offering may be required to pay, on application (subject to application channel), the Offer Price of HK\$13.15 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565%.

EXPECTED TIMETABLE

Hong Kong Public Offering commences 9:00 a.m. on Friday,
June 13, 2025

Latest time to complete electronic applications under
the **HK eIPO White Form** service through
the designated website www.hkeipo.hk 11:30 a.m. on Wednesday,
June 18, 2025

Application lists open 11:45 a.m. on Wednesday,
June 18, 2025

Latest time to give **electronic application**
instructions to HKSCC. 12:00 noon on Wednesday,
June 18, 2025

Latest time to complete payment of
HK eIPO White Form applications by
effecting internet banking transfer(s) or
PPS payment transfer(s) 12:00 noon on Wednesday,
June 18, 2025

If you are instructing your **broker** or **custodian** who is a HKSCC Participant to give **electronic application instructions** via HKSCC's FINI System terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists close 12:00 noon on Wednesday,
June 18, 2025

(1) Announcement of the level of applications
in the Hong Kong Public Offering,
the level of indications of interest in the
International Offering and the basis of
allocation of the Hong Kong Offer Shares to
be published on our website at
www.transthera.com and the website of the
Hong Kong Stock Exchange at
www.hkexnews.hk on or before 11:00 p.m. on Friday,
June 20, 2025

(2) Results of allocations in the Hong Kong Public Offering to be available through a variety of channels as described in “How to Apply for Hong Kong Offer Shares – B. Publication of Results” in this prospectus from Friday, June 20, 2025

(3) A full announcement of the Hong Kong Public Offering containing (1) and (2) above to be published on the website of the Stock Exchange at www.hkexnews.hk and the Company’s website at www.transthera.com from Friday, June 20, 2025

Result of allocations in the Hong Kong Public Offering (with successful applicants’ identification document numbers, where appropriate) will be available at the “Allotment Results” page at www.tricor.com.hk/ipo/result (or www.hkeipo.hk/IPOResult) with a “search by ID” function from Friday, June 20, 2025

H Share certificates in respect of wholly or partially successful applications to be dispatched or deposited into CCASS on or before Friday, June 20, 2025

HK eIPO White Form e-Auto Refund payment instructions/refund cheques in respect of wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering to be dispatched on or before. Monday, June 23, 2025

Dealings in H Shares on the Hong Kong Stock Exchange expected to commence at 9:00 a.m. on Monday, June 23, 2025

Note: Unless otherwise stated, all dates and times refer to Hong Kong local dates and times.

SETTLEMENT

Subject to the granting of listing of, and permission to deal in, our H Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Hong Kong Stock Exchange or any other date as HKSCC chooses. Settlement of any transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and HKSCC Operational Procedures in effect from time to time. Investors should seek the advice of their stockbroker or other professional advisors for details of the settlement arrangements as such arrangements may affect their rights and interests. All necessary arrangements have been made for our H Shares to be admitted into CCASS.

PUBLICATION OF RESULTS

We expect to announce the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on the website of the Hong Kong Stock Exchange at **www.hkexnews.hk** and our website at **www.transthera.com** by no later than 11:00 p.m. on June 20, 2025 (Hong Kong time).

The results of allocations and the identification document numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares — B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering are not fulfilled in accordance with the section headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Hong Kong Stock Exchange trading fee, will be refunded (subject to application channels), without interest.

No temporary document of title will be issued in respect of the H Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time) on the Listing Date, **provided that** the Global Offering has become unconditional in all respects, and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of the H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time) on June 23, 2025, dealings in our Company’s H Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. (Hong Kong time) on June 23, 2025. The H Shares will be traded in board lots of 500 H Shares each. The stock code of our Company’s H Shares will be 2617.

This announcement is available for viewing on the website of the Company at **www.transthera.com** and the website of the Stock Exchange at **www.hkexnews.hk**.

By order of our Board
TransThera Sciences (Nanjing) Inc.
藥捷安康(南京)科技股份有限公司

Dr. Frank Wu

Chairperson, Chief executive officer and Executive Director

Hong Kong, June 13, 2025

As at the date of this announcement, the board of directors of our Company comprises Dr. Frank Wu and Mr. Wu Di as executive Directors, Ms. Jia Zhongxin and Dr. Yi Hua as non-executive Directors, and Ms. Chui Hoi Yam, Ms. Zheng Zhelan and Mr. Li Shu Pai as independent non-executive Directors.